Enrofloxacin is an antibiotic derivative of quinolone carboxylic acid with broad spectrum activity against gram-positive and gram-negative bacteria, as well as Mycoplasma sp. Additionally, enrofloxacin inhibits Topo II α (DNA gyrase) and has been used to study quinolone resistance in the Salmonella enterica subspecies enterica serovar Choleraesuis, Mycoplasma gallisepticum and Escherichia coli.
1. Schroder, J., et al., 1989. Enrofloxacin: a new antimicrobial agent. Journal of the South African Veterinary Association. 60(2): 122-4. PMID: 2691696
2. Usui, Masaru., et al., 2009. Intracellular concentrations of enrofloxacin in quinolone-resistant Salmonella enterica subspecies enterica serovar Choleraesuis. International journal of antimicrobial agents. 34(6): 592-5. PMID: 19733466
3. Forcella, C., et al., 2010. Characterization of quinolone resistance in Escherichia coli strains of animal origin from Italy. Journal of chemotherapy (Florence, Italy). 22(3): 165-8. PMID: 20566420
4. Usui, Masaru., et al., 2011. Contribution of enhanced efflux to reduced susceptibility of Salmonella enterica serovar Choleraesuis to fluoroquinolone and other antimicrobials. The Journal of veterinary medical science / the Japanese Society of Veterinary Science. 73(2): 279-82. PMID: 20953129
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.